Version history

{
  "session_id": "sess_SDA-2026-04-02-gap-2026-04-01-gap-006_task_9aae8fc5",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "scidex.core.llm.complete",
  "action": "assess",
  "content": "# Feasibility Assessment: Neurodegeneration Therapeutic Hypotheses\n\n## Executive Summary\n\n| Hypothesis | Primary Modality | Feasibility Tier | Timeline | Cost Range |\n|------------|------------------|------------------|----------|------------|\n| **7. cGAS-STING/Tau** | STING inhibitors | **Tier 1** | 5-8 yr | $100-200M |\n| **2. TREM2/DAM** | Agonist antibodies | **Tier 2** | 6-9 yr | $150-250M |\n| **6. Astrocyte/GRN** | MCT4 modulators | **Tier 2** | 7-10 yr | $150-250M |\n| **1. TDP-43/Splicing** | ASOs | **Tier 3** | 10-12 yr | $150-300M |\n| **3. Lysosome/αSyn** | TRPML1 agonists | **Tier 3** | 10-15 yr | $200-400M |\n| **5. N-acetylation** | Enzyme activators | **Tier 4** | 12-15 yr | $300M+ |\n| **4. circHomer1a** | Gene therapy | **Tier 5** | 15+ yr | $300M+ |\n\n---\n\n## Hypothesis 7: cGAS-STING Pathway in Tau Propagation\n**Revised Confidence: 0.76** | **Feasibility Tier: 1**\n\n### Druggability — HIGH\nSTING is one of the most actively drugged targets in neurodegeneration currently. Multiple BBB-penetrant small-molecule STING inhibitors are in active development (HTT-SAM? no—STING inhibitors such as C-176, H-151, and newer optimized analogs show CNS exposure). cGAS inhibitors are earlier but structurally tractable. Downstream readouts (IFN-β, IRF3 phosphorylation, CXCL10) are quantifiable via CSF cytokines and provide pharmacodynamic markers. **Druggability score: 7/10**\n\n### Biomarkers — GOOD\nThe pathway generates measurable, clinically actionable biomarkers:\n- **CSF cytokines**: IP-10, IFN-β, and inflammatory panels elevated in AD/tauopathy brains provide target engagement readouts\n- **Neuroinflammatory PET**: [¹¹C]-PK11195 and newer TSPO ligands measure microglial activation; newer-generation translocator protein tracers offer improved signal-to-noise\n- **Patient selection**: No single biomarker definitively enriches for cGAS-STING hyperactivation, but inflammatory CSF profiles combined with Braak stage may stratify candidates\n- **Gap**: No validated companion diagnostic; reliance on indirect neuroinflammatory markers\n\n### Model Systems — ROBUST\n- P301S tauopathy mice are well-characterized with established readouts\n- Human post-mortem tissue shows Type I interferon response signatures across AD and Pick's disease\n- iPSC-derived neurons and microglia allow human mechanistic studies\n- **Limitation**: Mouse CNS immune architecture differs from human; microglial density and responses are not fully conserved\n\n### Clinical Development Constraints — MODERATE\n- **Regulatory pathway**: Reasonable precedent—anti-inflammatory approaches in neurodegeneration have regulatory frameworks; FDA/NDA pathway for CNS immunomodulation exists\n- **Patient selection**: Requires stratification beyond clinical diagnosis; inflammatory \"hot\" vs. \"cold\" tauopathy may have different treatment responses\n- **Comparator arm design**: Ethical—standard of care (acetylcholinesterase inhibitors) may confound results\n- **Primary endpoint**: Cognitive measures are established but insensitive; composite cognitive-motor endpoints preferred\n\n### Safety — MANAGEABLE\n- **Peripheral immunity risk**: STING is widely expressed; chronic systemic STING inhibition may impair innate antiviral responses\n- **BBB-penetrant inhibitor margin**: Preclinical data suggest adequate safety windows, but chronic CNS immunomodulation risks infection susceptibility and autoimmune-like effects\n- **Mouse data**: STING knockout and inhibitor-treated mice show increased susceptibility to viral infections but generally tolerated otherwise\n- **Monitoring required**: Peripheral cytokine panels, infection surveillance, and regular neurologic assessment\n\n### Timeline/Cost Realism — 5-8 years to Phase II, $100-200M\nMultiple STING inhibitor programs exist, reducing de-risking burden. Phase I could initiate within 3-4 years if a BBB-penetrant lead compound advances. **This is the most translationally mature hypothesis in the set.**\n\n---\n\n## Hypothesis 2: TREM2-Dependent Microglial State Transition\n**Revised Confidence: 0.61** | **Feasibility Tier: 2**\n\n### Druggability — MODERATE-HIGH\nAntibody therapeutics against TREM2 are actively in development (AL002c/Alector, PRJ-3070/Prevail). The target is well-validated extracellular with clear structure-activity relationships. However:\n- **BBB penetration**: Monoclonal antibodies require active transport mechanisms or BBB-shuttle technologies—currently a significant limitation\n- **Target engagement marker**: Soluble TREM2 (sTREM2) in CSF is measurable and serves as a pharmacodynamic readout\n- **Downstream SYK pathway**: More challenging to drug selectively; SYK inhibitors are in oncology but carry toxicity concerns\n- **Druggability score: 6/10**\n\n### Biomarkers — MODERATE\n- **sTREM2 in CSF**: Acceptable pharmacodynamic marker for target engagement\n- **Neuroinflammatory PET**: Microglial activation imaging can serve as downstream readout\n- **DAM signature transcripts**: Single-cell RNA-seq from blood or CSF cells can track transcriptomic states (research use only currently)\n- **Patient selection**: TREM2 variant carriers represent obvious enriched population; however, R47H/R62H carriers are only a subset of AD patients\n- **Gap**: No validated DAM-state biomarker for routine clinical use; snRNA-seq remains research-grade\n\n### Model Systems — ADEQUATE WITH CAVEATS\n- **",
  "tokens_used": "1333",
  "persona_id": "persona-domain_expert"
}